Open AccessTreatment Outcome and Prognostic Factors for Patients with Bone‐Only Metastases of Breast Cancer: A Single‐Institution Retrospective Analysis
Author(s) -
Niikura Naoki,
Liu Jun,
Hayashi Naoki,
Palla Shana L.,
Tokuda Yutaka,
Hortobagyi Gabriel N.,
Ueno Naoto T.,
Theriault Richard L.
Publication year - 2011
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2010-0350
Subject(s) - medicine , oncology , breast cancer , bone metastasis , chemotherapy , metastatic breast cancer , metastasis , cancer , asymptomatic , radiation therapy
Purpose. Limited information is available about the optimal management and clinical outcome of bone‐only metastases in breast cancer patients. The objective of this study was to define prognostic factors for patients with bone‐only metastases. Our second objective was to compare progression‐free survival (PFS) and overall survival (OS) between patients with hormone receptor (HR) + tumors and bone‐only metastases who received combinatory therapy (chemotherapy followed by endocrine therapy, or endocrine therapy combined with molecular targeted therapy) and those treated with endocrine or chemotherapy alone. Patients and Methods. We retrospectively identified 351 breast cancer patients diagnosed with bone‐only metastasis in 1997–2008 at our institution. Results. Patients with metastasis detected at the time of their primary breast cancer diagnosis (rather than at recurrence), a single metastasis, or asymptomatic bone disease had a longer PFS interval, and patients with a performance status of 0–1, a single metastasis, or asymptomatic bone disease had a longer OS time. Among patients with HR + human epidermal growth factor receptor (HER)‐2 − disease, combinatory therapy was associated with longer PFS and OS times than with endocrine therapy. In multivariate analyses, combinatory therapy was not associated with longer PFS or OS times than with endocrine therapy. Among patients with HER‐2 + disease, trastuzumab led to a longer PFS interval but no difference in the OS time. Conclusion. Our results indicate that, for HR + disease, a prospective trial of chemotherapy followed by endocrine therapy is warranted to determine whether it prolongs survival more than endocrine therapy alone in patients with bone‐only metastases.